The Financial

Leen Kawas on Redefining Capital Efficiency in Biotechnology Development

The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional drug development programs routinely require ...
Business Insider

BPGbio Wins 2025 AI Drug Development Innovation Award from Biotech Breakthrough Awards

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...
Fierce Biotech

GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

The use of AI in the drug development process

AI could review data sets to assist clinical scientists ...
STAT

Biotech leaders say uncertainty at FDA threatens drug development

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. BOSTON — Replimune Group and ...
Business Wire

AI in Biotechnology Research Report 2025-2030: Growing Need for More Effective Drug Discovery and Development Process and Shift to Personalized Medicine Bolster Growth ...

DUBLIN--(BUSINESS WIRE)--The "AI in Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for AI in biotechnology was valued at $3.8 billion in ...

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...
Fierce Biotech

GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...
The Manila Times

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Inc. ('Cosmos Health' or the 'Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its ...
STAT

FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...